Todd M. Hutton

Anew Era TMS & Psychiatry Brings TMS Therapy to Dallas, TX

Retrieved on: 
Thursday, July 29, 2021

DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.

Key Points: 
  • DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.
  • Anew Era TMS & Psychiatry offers patients their very best chance for successful depressive symptomatic relief through the latest, most advanced, FDA cleared, non-medicinal treatment solution.
  • Breanna Splain, Managing Partner and Chief Strategic Officer at Anew Era TMS & Psychiatry, began as one of the first employees of Anew Era TMS & Psychiatry.
  • During a TMS Treatment, the electromagnetic currents stimulate nerve cells, activating regions of the brain that have become less active.

Dr. Randy Pardell Announced as President of the Clinical TMS Society

Retrieved on: 
Thursday, June 17, 2021

POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.

Key Points: 
  • POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.
  • Dr. Pardell's appointment was confirmed at the Clinical TMS Annual Meeting currently being held in West Palm Beach, Florida.
  • The Clinical TMS Society is an international professional association dedicated to optimizing clinical practice, awareness, and accessibility of Transcranial Magnetic Stimulation therapy.
  • Dr. Pardell has served on the Board of Directors of the Clinical TMS Society and as the Vice President 2020-21.

Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting

Retrieved on: 
Wednesday, June 9, 2021

MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.

Key Points: 
  • MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.
  • The CTMSS, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS), will hold its yearly meeting June 10-12 in West Palm Beach, Florida.
  • Its an honor and exciting to present new findings at the Clinical TMS Society Meeting, from theNeuroStar Outcomes Registry, the largest depression registry in the world, said Harold A. Sackeim,PhD, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University, and presenter at the Clinical TMS Society Annual Meeting.
  • Visit the Clinical TMS Societys website to learn more about the annual meeting.

Neuronetics® Celebrates 100,000 Treatment Milestone for Southern California TMS Center

Retrieved on: 
Monday, May 17, 2021

b'MALVERN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders announced today Southern California TMS Center , a NeuroStar\xc2\xae Advanced Therapy provider with 12 treatment centers across Southern California, has delivered more than 100,000 NeuroStar transcranial magnetic stimulation (TMS) treatments.

Key Points: 
  • b'MALVERN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders announced today Southern California TMS Center , a NeuroStar\xc2\xae Advanced Therapy provider with 12 treatment centers across Southern California, has delivered more than 100,000 NeuroStar transcranial magnetic stimulation (TMS) treatments.
  • is the immediate past President of the Clinical TMS Society and was one of the first Neurostar providers following FDA approval in 2008.\n\xe2\x80\x9cWe\xe2\x80\x99re extremely thankful for passionate customers, like Dr. Hutton of Southern California TMS Center, who remain dedicated to making NeuroStar treatment accessible to as many patients as possible,\xe2\x80\x9d said Keith J. Sullivan, President and CEO of Neuronetics.
  • NeuroStar Advanced Therapy for Mental Health is a non-drug, non-invasive treatment for adults with Major Depressive Disorder (MDD) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.2,3 NeuroStar treatment is available in 900 doctors\xe2\x80\x99 offices and hospitals in the U.S., and many of these NeuroStar practices, like Southern California TMS Center, have continued to offer mental health services throughout the COVID-19 pandemic.\n\xe2\x80\x9cSouthern California TMS Center is committed to providing the experience, expertise and quality care to all of our patients, especially in these uncertain times,\xe2\x80\x9d said Dr. Todd Hutton, M.D., Chief Medical Director at Southern California TMS Center.
  • NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan\xe2\x80\x99s national health insurance.

NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols

Retrieved on: 
Tuesday, February 23, 2021

The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.

Key Points: 
  • The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.
  • Since its launch, it has grown into the largest registry focused on outcomes for depression treatment.
  • Im grateful to the NeuroStar providers who contribute to the Outcomes Registry; it is research like this that informs treatment progress and advancements.
  • The research published in Brain Stimulation follows the publication of registry data in the Journal of Affective Disorders in December 2020, which suggested NeuroStar Advanced Therapy be studied and evaluated as a first-line treatment for Major Depressive Disorder.

Greenbrook TMS Announces Director Resignation

Retrieved on: 
Friday, January 15, 2021

Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) announced today that Mr. Stephan Roker has provided notice of his intention to resign as a director of the Company, effective today, citing the existence of previously unforeseen conflicts of interest as the reason for his resignation.

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) announced today that Mr. Stephan Roker has provided notice of his intention to resign as a director of the Company, effective today, citing the existence of previously unforeseen conflicts of interest as the reason for his resignation.
  • Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.

Greenbrook TMS to Participate at the 13th Annual LD Micro Main Event Conference

Retrieved on: 
Monday, December 7, 2020

Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, is pleased to announce that Bill Leonard, Chief Executive Officer, will present at the 13th Annual LD Micro Main Event Conference, on December 15, 2020 at 9:40 a.m. (Eastern Time).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, is pleased to announce that Bill Leonard, Chief Executive Officer, will present at the 13th Annual LD Micro Main Event Conference, on December 15, 2020 at 9:40 a.m. (Eastern Time).
  • Interested parties can register to attend at the following link: https://ve.mysequire.com/
    Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.

Greenbrook TMS Announces Dates for Its Third Quarter 2020 Financial Results

Retrieved on: 
Tuesday, October 20, 2020

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Key Points: 
  • For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.
  • Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • Greenbrook has provided more than 500,000 TMS treatments to over 14,000 patients struggling with depression.

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, October 13, 2020

The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive option for treating depression.

Key Points: 
  • The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive option for treating depression.
  • The study authors found that treatment with NeuroStar Advanced Therapy showed robust antidepressant effects, greater than in early open-label studies of transcranial magnetic stimulation (TMS).
  • The clinical benefit from NeuroStar Advanced Therapy reported by both patients and clinicians in routine clinical practice compared favorably with alternative interventions for treatment-resistant depression.
  • The authors analyzed two sample sets of more than 5,000 patients across 103 practice sites, evaluating patient-rated and clinician-rated clinical outcomes data from treatment with NeuroStar.

NeuroStar® Advanced Therapy Providers Offer Free TMS Consultations During National Depression Awareness Month

Retrieved on: 
Thursday, October 1, 2020

Our dedicated providers offer not only information, but hope during each and every consultation as they educate patients and their loved ones about NeuroStar Advanced Therapy that may offer remission from depression.

Key Points: 
  • Our dedicated providers offer not only information, but hope during each and every consultation as they educate patients and their loved ones about NeuroStar Advanced Therapy that may offer remission from depression.
  • In addition to free consults, many providers also offer free depression screenings.
  • To join the conversation during National Depression Awareness Month and to help destigmatize depression, follow NeuroStar on Face b ook , Inst a g ram and Twit t e r ,and access additional resources at www.NeuroStar.com/DepressionAwareness .
  • Its first commercial product is a transcranial magnetic stimulation (TMS) device called the NeuroStar Advanced Therapy System.